StreetInsider.com News Articles

Form 8-K AbCellera Biologics Inc. For: Jun 17

Wed, 17 Jun 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260617/26658871.html

Form 8-K AbCellera Biologics Inc. For: Jun 17

Wed, 17 Jun 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260617/26658871.html

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

Jazz Pharmaceuticals (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) have entered a preclinical research collaboration, option and license agreement to discover and develop T-cell engaging multispecific antibodies targeting gastrointestinal cancers and other solid tumors.

Under the agreement, AbCellera will conduct discovery and early-stage research for two initial programs, with a commitment to begin a third program within 12 months. Jazz holds an exclusive option to develop and commercialize any resulting therapies on a worldwide basis.

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera ink antibody research deal

Wed, 17 Jun 2026 07:01:02 -0400

AbCellera will receive $56 million in upfront payments for the first two programs, plus an additional $28 million upon initiation of the third program. If Jazz exercises its

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Wed, 17 Jun 2026 07:00:00 -0400

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop